Reported 12 months ago
The U.S. Food and Drug Administration approved Eli Lilly's Alzheimer's drug, donanemab, for early Alzheimer's patients, becoming the second drug approved for slowing the disease progression. The drug, branded as Kisunla, was priced at $695.65 per vial, totaling $32,000 for a year of treatment. The approval aligned with expert recommendations stating the benefits of the drug outweighed its risks.
Source: YAHOO